Celgene Corporation

CELG

(NASDAQ)

Industri: Health Care seperator

Sektor: Pharmaceuticals & Biotechnology

$ 92,71 <%= Resources.Global.txtUp %>

Opdateret 14-08-2018

Ændring %	0,80%
Ændring	0,74
Volume	1.689.971
Høj	$ 93,33
Lav	$ 91,90
Åben	$ 91,94
ISIN
Seneste luk	$ 91,97
# af aktier	703,36M
Markedsværdi	65.209M USD

I dag

Market closed

Markedet er lukket, åbner klokken 15:30


Kursudvikling	Seneste	1 uge	1 måned	3 mdr	6 mdr	1 år

	92,71	1,6%	8,2%	13,1%	-3,6%	-29,4%

Dansk
Engelsk
Fondsbørsmeddelelser

	14 jun	Report: Developing Opportunities within Equinix, Sonus Networks, Celgene, National Grid, Atlas Air Worldwide, and Copa Holdings, S.A. — Future Expectations, Projections Moving into 2018

	29 maj	DEADLINE TODAY: The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)

	25 maj	$100,000 Threshold: Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Celgene Corporation Investors (CELG)

	23 maj	CELG EQUITY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018

	22 maj	LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Celgene Corporation To Contact The Firm

	22 maj	INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG

	22 maj	FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation (Nasdaq:CELG) To Contact The Firm

	19 maj	CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG

	15 maj	Nohla Therapeutics Announces Closing of $45 Million Series B Financing

	12 maj	CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG

Flere nyheder

	Seneste	1 uge	1 måned	3 mdr	6 mdr	1 år	ÅTD

Konkurrenter

Shire PLC ORD 5P	4.428,74	-1,6%	2,0%	5,9%	39,3%	15,2%	13,6%

Bristol-Myers Squibb Company	59,96	-0,3%	5,5%	14,6%	-13,1%	3,6%	-2,2%

Johnson & Johnson	129,50	-1,3%	2,8%	3,5%	-1,3%	-2,9%	-7,3%

Merck & Company Inc (new)	66,46	-0,3%	5,7%	12,3%	18,7%	6,3%	18,1%

Pfizer Inc	40,71	-1,7%	8,5%	14,1%	14,0%	22,0%	12,4%

Amgen Inc	195,76	-0,2%	-0,1%	13,6%	6,6%	15,1%	12,6%

Gilead Sciences Inc	77,31	0,5%	-0,1%	15,4%	-5,2%	5,7%	7,9%

Vertex Pharmaceuticals Incorpo..	175,93	0,4%	-2,5%	13,1%	9,3%	15,2%	17,4%

Astrazeneca PLC ORD SHS $0.25	6.018,07	0,5%	9,4%	13,7%	27,7%	35,0%	17,5%

Novartis AG	82,14	-1,7%	4,3%	6,1%	-5,2%	-2,3%	-2,2%

Takeda PHARM.CO.LTD.	36,65	-0,9%	3,7%	3,3%	-17,0%	-19,5%	-21,7%

Biogen Inc	343,63	-1,8%	-1,4%	24,5%	14,8%	19,3%	7,9%

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Instrumenter	Kurs	Ændring
Shire PLC OR..	4.428,74	-0,4%
Bristol-Myer..	59,96	0,9%
Johnson & Jo..	129,50	-0,6%
Merck & Comp..	66,46	-0,4%
Pfizer Inc	40,71	-0,2%
Amgen Inc	195,76	0,1%	99,38,38,50,64,61,45,53,51,51
Gilead Scien..	77,31	0,0%	81,53,63,61,55,40,40,55,48,51
Vertex Pharm..	175,93	0,5%	16,66,56,47,54,52,40,18,1,32
Astrazeneca ..	6.018,07	-0,6%
Novartis AG	82,14	-0,4%
Takeda PHARM..	36,65	0,2%	0,0,0,0,0,100,100,100,100,100
Biogen Inc	343,63	0,8%	0,84,68,58,50,40,48,29,9,14

Celgene Corporation

Nyheder om Celgene Corporation

Relaterede

Celgene Corporation

Nyheder om Celgene Corporation

Relaterede

Firmaprofil

Peers